FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169351080> ?p ?o ?g. }

• W2169351080 endingPage "1325" @default.
• W2169351080 startingPage "1317" @default.
• W2169351080 abstract "Background Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30–65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy. Methods This randomised trial was done at 36 centres in the USA and Puerto Rico. Women with operable HER2-positive invasive breast cancer were randomly assigned (1:1) with a biased coin minimisation algorithm, stratified for age, tumour size, and hormone receptor status. Neither patients nor investigators (except for a cardiac safety review panel) were masked to treatment assignment. Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2 (FEC-75) on day 1 of a 21-day cycle for four cycles followed by paclitaxel 80 mg/m2 and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for 12 weeks followed by four cycles of FEC-75 (on day 1 of each 21-day cycle) and once-weekly trastuzumab, in the same doses as the sequential group. Surgery, including evaluation of the axilla, was done within 6 weeks of completion of neoadjuvant treatment. The primary outcome was the percentage of patients who had a pathological complete response in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00513292. Findings From Sept 15, 2007, to Dec 15, 2011, 282 women were enrolled (140 in the sequential group, 142 in the concurrent group). Two patients in the sequential group withdrew consent before starting treatment. 78 of 138 (56·5%, 95% CI 47·8–64·9) patients who received sequential treatment had a pathological complete response in the breast versus 77 of 142 (54·2%, 95% CI 45·7–62·6) who received concurrent treatment (difference 2·3%, 95% CI −9·3 to 13·9). No treatment-related deaths occurred. The most common severe toxic effects were neutropenia (35 [25·3%] of 138 patients in the sequential group vs 45 [31·7%] of 142 patients in the concurrent group) and fatigue (six [4·3%] vs 12 [8·5%]). Left ventricular ejection fraction dropped below the institutional lower limit of normal at week 12 in one (0·8%) of 130 patients who received sequential treatment and four (2·9%) of 137 patients who received concurrent treatment; by week 24, it had dropped below this limit in nine (7·1%) of 126 patients and in six (4·6%) of 130 patients, respectively. Interpretation Concurrent administration of trastuzumab with anthracyclines offers no additional benefit and is not warranted. Funding US National Cancer Institute. Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30–65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy. This randomised trial was done at 36 centres in the USA and Puerto Rico. Women with operable HER2-positive invasive breast cancer were randomly assigned (1:1) with a biased coin minimisation algorithm, stratified for age, tumour size, and hormone receptor status. Neither patients nor investigators (except for a cardiac safety review panel) were masked to treatment assignment. Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2 (FEC-75) on day 1 of a 21-day cycle for four cycles followed by paclitaxel 80 mg/m2 and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for 12 weeks followed by four cycles of FEC-75 (on day 1 of each 21-day cycle) and once-weekly trastuzumab, in the same doses as the sequential group. Surgery, including evaluation of the axilla, was done within 6 weeks of completion of neoadjuvant treatment. The primary outcome was the percentage of patients who had a pathological complete response in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00513292. From Sept 15, 2007, to Dec 15, 2011, 282 women were enrolled (140 in the sequential group, 142 in the concurrent group). Two patients in the sequential group withdrew consent before starting treatment. 78 of 138 (56·5%, 95% CI 47·8–64·9) patients who received sequential treatment had a pathological complete response in the breast versus 77 of 142 (54·2%, 95% CI 45·7–62·6) who received concurrent treatment (difference 2·3%, 95% CI −9·3 to 13·9). No treatment-related deaths occurred. The most common severe toxic effects were neutropenia (35 [25·3%] of 138 patients in the sequential group vs 45 [31·7%] of 142 patients in the concurrent group) and fatigue (six [4·3%] vs 12 [8·5%]). Left ventricular ejection fraction dropped below the institutional lower limit of normal at week 12 in one (0·8%) of 130 patients who received sequential treatment and four (2·9%) of 137 patients who received concurrent treatment; by week 24, it had dropped below this limit in nine (7·1%) of 126 patients and in six (4·6%) of 130 patients, respectively. Concurrent administration of trastuzumab with anthracyclines offers no additional benefit and is not warranted." @default.
• W2169351080 created "2016-06-24" @default.
• W2169351080 creator A5002740532 @default.
• W2169351080 creator A5002818963 @default.
• W2169351080 creator A5017411324 @default.
• W2169351080 creator A5017670549 @default.
• W2169351080 creator A5033544737 @default.
• W2169351080 creator A5053783063 @default.
• W2169351080 creator A5055832110 @default.
• W2169351080 creator A5057135409 @default.
• W2169351080 creator A5071158497 @default.
• W2169351080 creator A5076426660 @default.
• W2169351080 creator A5082661564 @default.
• W2169351080 date "2013-12-01" @default.
• W2169351080 modified "2023-10-18" @default.
• W2169351080 title "Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial" @default.
• W2169351080 cites W1867197625 @default.
• W2169351080 cites W1955397179 @default.
• W2169351080 cites W1983996954 @default.
• W2169351080 cites W1984274637 @default.
• W2169351080 cites W1987326983 @default.
• W2169351080 cites W1992234802 @default.
• W2169351080 cites W2062192964 @default.
• W2169351080 cites W2104337757 @default.
• W2169351080 cites W2107103026 @default.
• W2169351080 cites W2111578514 @default.
• W2169351080 cites W2118804515 @default.
• W2169351080 cites W2123591186 @default.
• W2169351080 cites W2124623816 @default.
• W2169351080 cites W2125239609 @default.
• W2169351080 cites W2132514250 @default.
• W2169351080 cites W2146384083 @default.
• W2169351080 cites W2147415463 @default.
• W2169351080 cites W2149908785 @default.
• W2169351080 cites W2316247073 @default.
• W2169351080 cites W2318605753 @default.
• W2169351080 cites W4239258335 @default.
• W2169351080 doi "https://doi.org/10.1016/s1470-2045(13)70502-3" @default.
• W2169351080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4176878" @default.
• W2169351080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24239210" @default.
• W2169351080 hasPublicationYear "2013" @default.
• W2169351080 type Work @default.
• W2169351080 sameAs 2169351080 @default.
• W2169351080 citedByCount "143" @default.
• W2169351080 countsByYear W21693510802013 @default.
• W2169351080 countsByYear W21693510802014 @default.
• W2169351080 countsByYear W21693510802015 @default.
• W2169351080 countsByYear W21693510802016 @default.
• W2169351080 countsByYear W21693510802017 @default.
• W2169351080 countsByYear W21693510802018 @default.
• W2169351080 countsByYear W21693510802019 @default.
• W2169351080 countsByYear W21693510802020 @default.
• W2169351080 countsByYear W21693510802021 @default.
• W2169351080 countsByYear W21693510802022 @default.
• W2169351080 countsByYear W21693510802023 @default.
• W2169351080 crossrefType "journal-article" @default.
• W2169351080 hasAuthorship W2169351080A5002740532 @default.
• W2169351080 hasAuthorship W2169351080A5002818963 @default.
• W2169351080 hasAuthorship W2169351080A5017411324 @default.
• W2169351080 hasAuthorship W2169351080A5017670549 @default.
• W2169351080 hasAuthorship W2169351080A5033544737 @default.
• W2169351080 hasAuthorship W2169351080A5053783063 @default.
• W2169351080 hasAuthorship W2169351080A5055832110 @default.
• W2169351080 hasAuthorship W2169351080A5057135409 @default.
• W2169351080 hasAuthorship W2169351080A5071158497 @default.
• W2169351080 hasAuthorship W2169351080A5076426660 @default.
• W2169351080 hasAuthorship W2169351080A5082661564 @default.
• W2169351080 hasBestOaLocation W21693510802 @default.
• W2169351080 hasConcept C121608353 @default.
• W2169351080 hasConcept C126322002 @default.
• W2169351080 hasConcept C143998085 @default.
• W2169351080 hasConcept C2776694085 @default.
• W2169351080 hasConcept C2776755627 @default.
• W2169351080 hasConcept C2776802502 @default.
• W2169351080 hasConcept C2777292972 @default.
• W2169351080 hasConcept C2777511904 @default.
• W2169351080 hasConcept C2778292576 @default.
• W2169351080 hasConcept C2779786085 @default.
• W2169351080 hasConcept C2780835546 @default.
• W2169351080 hasConcept C530470458 @default.
• W2169351080 hasConcept C71924100 @default.
• W2169351080 hasConceptScore W2169351080C121608353 @default.
• W2169351080 hasConceptScore W2169351080C126322002 @default.
• W2169351080 hasConceptScore W2169351080C143998085 @default.
• W2169351080 hasConceptScore W2169351080C2776694085 @default.
• W2169351080 hasConceptScore W2169351080C2776755627 @default.
• W2169351080 hasConceptScore W2169351080C2776802502 @default.
• W2169351080 hasConceptScore W2169351080C2777292972 @default.
• W2169351080 hasConceptScore W2169351080C2777511904 @default.
• W2169351080 hasConceptScore W2169351080C2778292576 @default.
• W2169351080 hasConceptScore W2169351080C2779786085 @default.
• W2169351080 hasConceptScore W2169351080C2780835546 @default.
• W2169351080 hasConceptScore W2169351080C530470458 @default.
• W2169351080 hasConceptScore W2169351080C71924100 @default.
• W2169351080 hasIssue "13" @default.
• W2169351080 hasLocation W21693510801 @default.
• W2169351080 hasLocation W21693510802 @default.
• W2169351080 hasLocation W21693510803 @default.

• next